Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Phase 2

Withdrawn

Conditions: Anal Canal Squamous Cell Carcinoma

Interventions: Drug: BI 754091
Drug: BI 836880

First Posted Date: 2020-08-05

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT04499352

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Phase 2

Terminated

Conditions: Palmoplantar Pustulosis

Interventions: Drug: Spesolimab

First Posted Date: 2020-07-30

Last Posted Date: 2024-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 108

Registration Number: NCT04493424

Locations: 🇵🇱
Dermoklinika medical center, Lodz, Lodz, Poland
🇩🇪
Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

and more 63 locations

A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BI 1356225
Drug: Placebo

First Posted Date: 2020-06-25

Last Posted Date: 2021-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 87

Registration Number: NCT04447261

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 1569912
Drug: Placebo

First Posted Date: 2020-06-24

Last Posted Date: 2021-11-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT04445090

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1595043
Drug: Placebo

First Posted Date: 2020-06-19

Last Posted Date: 2024-02-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT04439838

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase 1

Recruiting

Conditions: Patients With Small Cell Lung Carcinoma and Other Neoplasms

Interventions: Drug: BI 764532 - parenteral 1
Drug: BI 764532 - parenteral 2

First Posted Date: 2020-06-12

Last Posted Date: 2024-12-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 282

Registration Number: NCT04429087

Locations: 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇪🇸
Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 8 locations

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894

First Posted Date: 2020-06-11

Last Posted Date: 2020-10-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT04426851

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

Phase 2

Terminated

Conditions: Depressive Disorder, Major

Interventions: Drug: BI 1358894
Drug: Placebo

First Posted Date: 2020-06-09

Last Posted Date: 2023-06-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT04423757

Locations: 🇺🇸
Science 37, Inc., Culver City, California, United States

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

Phase 1

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: Sham control of BI 764524
Drug: BI 764524

First Posted Date: 2020-06-09

Last Posted Date: 2024-05-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT04424290

Locations: 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States

and more 15 locations

A Study in Healthy Men to Compare 2 Different Formulations of Alteplase

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Alteplase (from modified manufacturing process)
Drug: Alteplase (from current manufacturing process)
Drug: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)

First Posted Date: 2020-06-05

Last Posted Date: 2023-04-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT04419493

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy